This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Medivation Inc (MDVN)

NASDAQ: Health Care

$96.97+1.99 | 2.10%
10/21/14 - 4:00 PM ET
  • Prev Close: 94.98
  • Day's Open: 95.86
  • Volume: 1.11M
  • Avg Vol: 1.16M
  • Shares Outstanding: 76.79M
  • Mkt Cap: 7.24B
  • Div: --
  • Div Yield: --
  • P/E: 325.07
  • EPS: -0.57
MDVN Day's Range
$95.65
$98.09
MDVN 52 Week Range
$48.15
$103.88
MDVN Business Summary
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients.View MDVN key stats
MDVN Performance as of Prev. Close
YTD
48.82%
3-Mo
34.69%
1-Yr
86.89%
3-Yr
1,010.23%
MDVN EPS Performance
1-Yr Ago
-0.57
2-Yrs Ago
-0.56
3-Yrs Ago
-0.56
MDVN Percentage in these ETFs
0.140%
0.110%
0.020%
0.012%
0.008%
MDVN News

Analysts Ratings for MDVN

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 11 11 10 10
Moderate Buy 0 0 0 0
Hold 2 3 4 4
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
GET MDVN ANALYST REPORT

Brokerage Partners

MDVN Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs